The management of diabetic macular oedema

• Main Authors: Adam H. Ross, MBChB, CertMedEd, MRCOphth, C. Clare Bailey, MD, MRCP, FRCOphth
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2011-04-01
• Series: Saudi Journal of Ophthalmology
• Online Access: http://www.sciencedirect.com/science/article/pii/S1319453411000129

Diabetic macular oedema (DMO) is a significant cause of visual loss in the working population. Focal/grid photocoagulation remains an effective treatment for DMO and the benchmark to which clinicians compare other newer treatment modalities. There are, however, patients who do not respond adequately or who are refractory to laser photocoagulation. This has led to the development of newer treatments such as the intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors as well as intravitreal corticosteroid releasing delivery systems. Cataract formation and raised intraocular pressure remain the major disadvantages of corticosteroid use. There is mounting evidence that intravitreal VEGF inhibitors with or without combined laser photocoagulation will become the gold standard treatment for DMO. Keywords: Diabetic macular oedema, Laser photocoagulation, Intravitreal steroids, VEGF inhibitors